Feb 11, 2021

New study provides insight into the molecular biology of colorectal cancer

In a new study published in the journal Cancer Biology & Therapy, Dr. Tai’s research group characterized the involvement of a multi-functional protein, called NPM1, in colorectal cancer growth and treatment resistance, providing the research community with a potential therapeutic target for the treatment of the disease.
Feb 04, 2021

World Cancer Day 2021

February 4 is World Cancer Day—a global initiative led by the Union for International Cancer Control. Patients, families, communities, clinicians, researchers and others are joining together to raise awareness and to act.

Here at Canada’s Michael Smith Genome Sciences Centre at BC Cancer, we are making significant strides in realizing the benefit of genomics in researching, understanding, diagnosing and treating cancer.

Feb 02, 2021


Our first petabase of sequencing data was recorded in December of 2015, 16 years from the creation of the GSC in 1999. In April of 2018, just two years and four months later, we recorded our second.  On Sunday, January 24, 2021 we hit another milestone—three petabases of sequencing data!
Jan 07, 2021

Molecular subtypes of common pancreatic cancers can be predicted from tumour characteristics

Gene expression analysis of pancreatic ductal adenocarcinoma (PDAC) tumours enables clinicians to stratify patients into molecular subgroups and select treatments that are best suited to each type; however, molecular subtyping remains cost-prohibitive and is not yet part of routine cancer care.

Dec 17, 2020

Study shows Canada Genome Centres primed for COVID-19 host sequencing

Large-scale genome sequencing initiatives frequently rely on datasets provided by different sequencing centres, all of which may employ different laboratory protocols, instruments and analytical methods that may introduce disparities in the data produced. When combining datasets generated at different institutions, how do researchers ensure consistency between datasets?    

Nov 26, 2020

Whole genome and transcriptome sequencing uncovers biomarkers predicting response to immune checkpoint inhibitors

The development of immune checkpoint inhibitors (ICI), a type of cancer therapy that helps the immune system fight tumours, was one of the most significant milestones in cancer treatment in the last decade. While ICI therapy has been used to treat different cancer types, it is not universally effective and relapsed disease occurs. A robust strategy for predicting which patients are likely to respond to ICIs is needed, enabling clinicians to select the best course of treatment for each patient.

Back to top